Ioana Kloos

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

Michael Wang, Javier Muñoz, André Goy et al. · Journal of Clinical Oncology · 2022 · 318 citations · Full text

Medicine, Hematology, Oncology +15

Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study

Karine Briot, M. Tubiana-Hulin, Laurent Bastit et al. · Breast Cancer Research and Treatment · 2009 · 117 citations · Full text

Medicine, Endocrinology, Oncology +17

Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study

Vincent Ribrag, Won Seog Kim, Réda Bouabdallah et al. · Haematologica · 2017 · 97 citations · Full text

Medicine, Oncology, Pharmacology +17

Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

Esperanza M. Algarín, Andrea Díaz-Tejedor, Pedro Mogollón et al. · Haematologica · 2019 · 56 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia

Franck Morschhauser, Louis Terriou, Bertrand Coiffier et al. · Investigational New Drugs · 2015 · 39 citations

Medicine, Oncology, Pharmacology +13